Patients treated with AR-15512 showed higher rates of at least a 10-mm improvement in unanesthetized Schirmer’s score, a metric of tear production.
Today the company announced that its experimental therapy halted disease progression in patients with early stages of a genetic eye condition that leads to blindness.
Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker’s conservative image.
The Danish drugmaker’s chief executive said the effects patients see after being on Wegovy would be an incentive for them to continue, although it may be “too early to tell.”
Given the need for Rebyota in the market, Ferring’s launch training strategy focused on high-engagement learning through a unique learning journey that empowered its commercial teams to appropriately educate providers on the product features, benefits, and applications. This article walks through how the company and its partners created an immersive product launch learning experience for the field team built upon an engaging and strategic curriculum and a user-friendly training and event platform.
Vertex still has an ongoing diabetes partnership with CRISPR, which gives it a non-exclusive license to the latter’s platform to develop a potential cure for type 1 diabetes.
2023 was a breakthrough year for cell and gene therapies, with seven FDA approvals in the U.S. and one in the European Union, according to the Alliance for Regenerative Medicine. Looking to 2024, the Washington, D.C.–based advocacy organization predicted that the sector could see up to 17 approvals in the U.S. and EU.
Today the company said it expects to return to revenue growth in 2025 when the ongoing decline in its COVID-19 vaccine business would bottom out, and that it would invest to scale up its oncology business thereafter.
The two companies are preparing to launch the drug in the second quarter of Eisai’s 2024/25 business year starting in April.
Aiolos focuses on therapies for respiratory and inflammatory conditions, and is currently developing ‘AIO-001’, a treatment for asthma which is ready to enter mid-stage clinical trials.
